Filter
1384
Text search:
drug
approval
Featured
91
410
Language
Document type
849
230
167
56
33
26
13
4
3
2
1
Countries / Regions
92
43
42
38
37
35
34
30
28
28
26
25
23
23
22
22
21
19
19
18
16
16
14
13
12
12
11
9
8
8
8
8
8
6
5
5
5
5
5
5
4
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
615
117
41
35
34
19
12
1
Toolboxes
169
132
101
74
72
64
35
25
25
24
21
17
12
11
11
11
9
6
5
5
4
2
1
Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program.
A Guide For Multicentre Trials in High-Burden Countries
54th directing council; 67th session of the regional Committee of WHO for the Americas
CD54/11, Rev. 1, 2 October 2015, Original: Spanish
Research Article
BMC Infectious Diseases 2012, 12:262; doi:10.1186/1471-2334-12-262
17–24 November 2015
4–15 February 2013
Report of a mission 20–24 April 2015
These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and Registration (MER) of the East African Community M
...
The Global Campaign Against Epilepsy “Out of the Shadows”
The National Tuberculosis Programme (NTP) of Rwanda (known as TB & ORD Division/IHDPC/RBC) is preparing to write their next National Strategic Plan and for this reason Rwanda was selected as a country to received technical assistance (TA) to conduct an assessment of their surveillance system using t
...
The Rwandan Ministry of Health recognizes the threat that Non-Communicable Diseases (NCDs) pose to health and development in Rwanda and in 2009 articulates strategies to respond to them in the Health Sector Strategic Plan 2012 - 2018 (HSSP3). Among other things, the plan calls for a national prevale
...
The purpose of these guidelines is to help health workers to participate in the process of continuous surveillance of safety and efficacy of the pharmaceutical products which are used in clinical practice, thus help to achieve the ultimate goal to make safer and more effective treatment available to
...
This document describes the key areas that national governments should consider for the introduction and scale-up of point-of-care (POC) diagnostics within national programmes, as new innovative POC technologies are being introduced into the market. The next steps taken to include these new innovati
...
Recent systematic reviews and meta-analysis of the impact of chemical-based mollusciciding (King et al., 2015, Sokolow et al., 2016) have concluded that regular mollusciciding is likely to contribute significantly towards elimination of schistosomiasis in high-risk areas. The WHO roadmap’s new foc
...
This year marked the beginning of the WHO biennium 2016-2017 action plan; this annual report highlights WHO’s key achievements in 2016
It also documents the extraordinary efforts by a broad coalition of government ministries, municipalities, international agencies, community groups, women’s or
...
